Close Menu

NEW YORK (GenomeWeb) – Medicare contractor Noridian has issued a final local coverage decision (LCD) for Myriad Genetics' Prolaris, a test for gauging prostate cancer aggressiveness.

In January this year, another Medicare contractor, Palmetto GBA, issued a final LCD on the same test when used for low- and very low-risk prostate cancer patients. Similarly, the final LCD from Noridian, which goes into effect on October 15, will cover testing for prostate cancer patients defined as low and very low risk by the National Comprehensive Cancer Network. 

To read the full story....

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Don't have a GenomeWeb or 360Dx account?
Register for Free.

The Financial Times reports the US bolstering its ability to track SARS-CoV-2 alterations.

The New York Times reports that Cedars-Sinai researchers have uncovered a new strain of SARS-CoV-2 in Southern California.

In Nucleic Acids Research this week: pan-cancer atlas focus on miRNA biogenesis mutations, methylation analysis of pig skeletal muscles, and more.

President-elect Joe Biden has nominated Eric Lander to serve as director of the Office of Science and Technology Policy, the Associated Press says.